Liminatus Pharma, Inc.
LIMN
$0.18
$0.00-2.17%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 429.14% | 276.79% | 473.14% | -- | 255.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 429.14% | 29.11% | 22.99% | -99.98% | -78.07% |
| Operating Income | -429.14% | -29.11% | -22.99% | 99.98% | 78.07% |
| Income Before Tax | -3,454.79% | -203.19% | 111.79% | 99.98% | 70.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3,454.79% | -203.19% | 111.79% | 99.98% | 70.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3,454.79% | -203.19% | 111.79% | 99.98% | 70.19% |
| EBIT | -429.14% | -29.11% | -22.99% | 99.98% | 78.07% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -2,200.76% | -96.22% | 108.93% | 100.00% | -89.86% |
| Normalized Basic EPS | -182.93% | -156.74% | 0.58% | 100.00% | -90.70% |
| EPS Diluted | -2,200.76% | -96.22% | 108.93% | 100.00% | -89.86% |
| Normalized Diluted EPS | -182.93% | -156.74% | 0.58% | 100.00% | -90.70% |
| Average Basic Shares Outstanding | 54.86% | 54.33% | 33.15% | 48.65% | -84.42% |
| Average Diluted Shares Outstanding | 54.86% | 54.33% | 33.15% | 48.65% | -84.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |